DelphX Announces Warrant Extension

Rhea-AI Summary

DelphX Capital Markets (OTCQB: DPXCF) is seeking TSX Venture Exchange approval to extend the exercise period of two sets of share purchase warrants. The company aims to extend 4,825,715 warrants exercisable at $0.30 per share to August 25, 2026, and 2,825,000 warrants exercisable at $0.15 per share to August 30, 2026.

Of these warrants, 1,929,286 are held by related parties, constituting a related party transaction. The transaction qualifies for exemption from formal valuation and minority approval requirements as the warrants' fair market value is below 25% of DelphX's market capitalization.

News Market Reaction

+25.71%

1 alert

+25.71% News Effect

On the day this news was published, DPXCF gained 25.71%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Toronto, Ontario--(Newsfile Corp. - August 22, 2025) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products, announces that it intends to seek approval of the TSX Venture Exchange to extend the exercise period of share purchase warrants.

DelphX intends to seek approval of the TSX Venture Exchange to extend the exercise period of (i) 4,825,715 share purchase warrants, exercisable at $0.30 per common share (issued pursuant to a private placement announced August 25, 2022) by one year to August 25, 2026, and (ii) 2,825,000 share purchase warrants, exercisable at $0.15 per common share (issued pursuant to a private placement announced August 30, 2023) by one year to August 30, 2026.

All other terms and conditions of the warrants will remain unchanged. The warrant extension is subject to acceptance by the TSX Venture Exchange.

A total of 1,929,286 warrants are held by parties who are considered to be "related parties" of DelphX Therefore, the amendment of Warrants constitutes a "related party transaction" as contemplated by Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions, and TSXV Policy 5.9 - Protection of Minority Security Holders in Special Transactions. However, the exemptions from formal valuation and minority approval requirements provided for can be relied upon as the fair market value of the Warrants does not exceed 25% of the market capitalization of DelphX.

About DelphX Capital Markets Inc.

DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables broker dealers to offer new private placement securities that provide for both fixed income and cryptocurrency solutions. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in:

• Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds and/or protection from losses in cryptocurrency holdings;

• Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade and/or cryptocurrency loss exposure of an underlying security or cryptocurrency in exchange for attractive returns.

All CPOs and CRNs are fully collateralized and held in custody by US Bank. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets.

For more information about DelphX, please visit www.delphx.com.

George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com
(718) 509-2160

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263541

FAQ

What is the purpose of DelphX's warrant extension announcement?

DelphX is seeking TSX Venture Exchange approval to extend the exercise period of two warrant sets by one year - 4,825,715 warrants at $0.30 and 2,825,000 warrants at $0.15 per share.

When will DPXCF's warrant extensions expire if approved?

If approved, the first set of warrants will expire on August 25, 2026, and the second set will expire on August 30, 2026.

How many DelphX warrants are held by related parties?

1,929,286 warrants are held by parties considered to be related parties of DelphX.

Does the DPXCF warrant extension require shareholder approval?

No, the transaction is exempt from formal valuation and minority approval requirements as the warrants' fair market value is below 25% of DelphX's market capitalization.